NASDAQ:SPRB Spruce Biosciences - SPRB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.04 +0.03 (+1.00%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.88▼$3.0950-Day Range$0.99▼$3.0952-Week Range$0.95▼$3.38Volume195,470 shsAverage Volume3.97 million shsMarket Capitalization$71.62 millionP/E RatioN/ADividend YieldN/APrice Target$6.80 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Spruce Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside196.1% Upside$9.00 Price TargetShort InterestBearish10.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.03) to ($1.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector316th out of 1,030 stocksPharmaceutical Preparations Industry147th out of 502 stocks 3.4 Analyst's Opinion Consensus RatingSpruce Biosciences has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Spruce Biosciences has a forecasted upside of 196.1% from its current price of $3.04.Amount of Analyst CoverageSpruce Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.02% of the float of Spruce Biosciences has been sold short.Short Interest Ratio / Days to CoverSpruce Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spruce Biosciences has recently increased by 77.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpruce Biosciences does not currently pay a dividend.Dividend GrowthSpruce Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SPRB. Previous Next 3.8 News and Social Media Coverage News SentimentSpruce Biosciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Spruce Biosciences this week, compared to 0 articles on an average week.Search Interest12 people have searched for SPRB on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows8 people have added Spruce Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spruce Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Spruce Biosciences is held by insiders.Percentage Held by Institutions84.21% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Spruce Biosciences are expected to grow in the coming year, from ($2.03) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spruce Biosciences is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spruce Biosciences is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpruce Biosciences has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Spruce Biosciences (NASDAQ:SPRB) StockSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.Read More Receive SPRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRB Stock News HeadlinesFebruary 1, 2023 | finance.yahoo.comSpruce Biosciences to Participate in the SVB Securities Global Biopharma ConferenceJanuary 31, 2023 | finance.yahoo.comSpruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?February 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 10, 2023 | marketwatch.comThinking about buying stock in SWVL Holdings, Apexigen, Sonnet BioTherapeutics, Spruce Biosciences, or Tilray?January 9, 2023 | msn.comPeering Into Spruce Biosciences's Recent Short InterestJanuary 9, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Hold Rating on Spruce Biosciences (SPRB)January 9, 2023 | finance.yahoo.comSpruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023January 6, 2023 | msn.comDecember Jobs Report Showing Easing Wage Pressures Lift US Equity FuturesFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 6, 2023 | finance.yahoo.comSpruce Biosciences Shares Skyrocket After Licensing Pact For Lead ProgramJanuary 5, 2023 | finance.yahoo.comSpruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in JapanNovember 16, 2022 | finance.yahoo.comJMP Says Forgotten Spruce Biosciences Could Draw Attention In 2023November 10, 2022 | finance.yahoo.comSpruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate UpdatesOctober 26, 2022 | finance.yahoo.comSpruce Biosciences to Participate in November Investor ConferencesSeptember 30, 2022 | reuters.comSpruce Biosciences IncSeptember 14, 2022 | seekingalpha.comSPRB Spruce Biosciences, Inc.August 30, 2022 | finance.yahoo.comSpruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 16, 2022 | seekingalpha.comSpruce Biosciences (SPRB) Investor Presentation - SlideshowAugust 10, 2022 | finance.yahoo.comSpruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateJune 1, 2022 | finance.yahoo.comSpruce Biosciences to Participate in June Investor ConferencesMay 31, 2022 | finance.yahoo.comSpruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual ConferenceMay 11, 2022 | finance.yahoo.comSpruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate UpdateMay 3, 2022 | finance.yahoo.comSpruce Biosciences to Participate in May Investor ConferencesApril 11, 2022 | finance.yahoo.comSpruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality OfficerMarch 16, 2022 | markets.businessinsider.comWhere Spruce Biosciences Stands With AnalystsMarch 14, 2022 | seekingalpha.comSpruce Biosciences hires new Chief Medical OfficerMarch 14, 2022 | finance.yahoo.comSpruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical OfficerSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SPRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRB Company Calendar Last Earnings11/10/2022Today2/02/2023Next Earnings (Estimated)3/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRB CUSIPN/A CIK1683553 Webwww.sprucebiosciences.com Phone415-655-4168FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+123.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.64% Return on Assets-40.08% Debt Debt-to-Equity Ratio0.05 Current Ratio7.76 Quick Ratio7.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.75 per share Price / Book0.64Miscellaneous Outstanding Shares23,560,000Free Float22,170,000Market Cap$71.62 million OptionableNot Optionable Beta2.25 Key ExecutivesMr. Michael G. Grey (Age 69)Exec. Chairman Comp: $65kMr. Samir M. Gharib CPA (Age 40)CPA, M.B.A., Pres & CFO Comp: $480kDr. Javier Szwarcberg M.D. (Age 52)M.P.H., CEO & Director Dr. Ralph William Charlton III (Age 52)M.D., Chief Medical Officer Dr. Libbie Mansell M.B.A.Ph.D., Chief Regulatory & Quality OfficerMs. P. J. RamtinSr. VP of Bus. OperationsMore ExecutivesKey CompetitorsGenprexNASDAQ:GNPXAnebulo PharmaceuticalsNASDAQ:ANEBGalera TherapeuticsNASDAQ:GRTXHCW BiologicsNASDAQ:HCWBMustang BioNASDAQ:MBIOView All CompetitorsInsiders & InstitutionsMarquette Asset Management LLCBought 4,267 shares on 1/12/2023Ownership: 0.290%Ergoteles LLCSold 18,868 shares on 11/14/2022Ownership: 0.098%Abingworth LLPBought 1,792,518 shares on 11/10/2022Ownership: 7.608%View All Institutional Transactions SPRB Stock - Frequently Asked Questions Should I buy or sell Spruce Biosciences stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRB shares. View SPRB analyst ratings or view top-rated stocks. What is Spruce Biosciences' stock price forecast for 2023? 6 Wall Street research analysts have issued 1-year price targets for Spruce Biosciences' stock. Their SPRB share price forecasts range from $3.00 to $20.00. On average, they anticipate the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 196.1% from the stock's current price. View analysts price targets for SPRB or view top-rated stocks among Wall Street analysts. How have SPRB shares performed in 2023? Spruce Biosciences' stock was trading at $1.0974 at the start of the year. Since then, SPRB shares have increased by 177.0% and is now trading at $3.04. View the best growth stocks for 2023 here. Are investors shorting Spruce Biosciences? Spruce Biosciences saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,210,000 shares, an increase of 77.1% from the December 31st total of 683,100 shares. Based on an average trading volume of 1,370,000 shares, the short-interest ratio is currently 0.9 days. Currently, 10.0% of the company's stock are sold short. View Spruce Biosciences' Short Interest. When is Spruce Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023. View our SPRB earnings forecast. How were Spruce Biosciences' earnings last quarter? Spruce Biosciences, Inc. (NASDAQ:SPRB) posted its earnings results on Thursday, November, 10th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.06. When did Spruce Biosciences IPO? (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO. What is Spruce Biosciences' stock symbol? Spruce Biosciences trades on the NASDAQ under the ticker symbol "SPRB." Who are Spruce Biosciences' major shareholders? Spruce Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Marquette Asset Management LLC (0.29%). Insiders that own company stock include Bali Muralidhar, Camilla V Simpson, Holdings A/S Novo and Venture Fund Iii L Rivervest. View institutional ownership trends. How do I buy shares of Spruce Biosciences? Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Spruce Biosciences' stock price today? One share of SPRB stock can currently be purchased for approximately $3.04. How much money does Spruce Biosciences make? Spruce Biosciences (NASDAQ:SPRB) has a market capitalization of $71.62 million. The company earns $-42,290,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. How can I contact Spruce Biosciences? The official website for the company is www.sprucebiosciences.com. The company can be reached via phone at 415-655-4168 or via email at investors@sprucebiosciences.com. This page (NASDAQ:SPRB) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.